Please select the option that best describes you:
What is your preferred bone modifying agent and frequency of dosing in patients with breast cancer and bony metastases?
Do you discuss patient visits and associated costs when making this decision?
Answer from: Medical Oncologist at Academic Institution
ASCO guidelines recommend zoledronic acid 4 mg every four weeks or every 12 weeks, or denosumab 120 mg subcutaneously every four weeks, or intravenous pamidronate 90 mg every four weeks. Present guidelines do not endorse one bone modifying agent over another, however, zoledronic acid and denosumab a...
Sign in or Register to read more